MED

Medifast Inc. (MED) | Rumor.io

Medifast

MED

Attention (50-day avg)0%

Attention rank (50-day avg)#2,846

Bullish sentiment (50-day avg)100%

Price to earnings ratio531.5

Market capitalization130.9M

Earnings per share-2.33

Dividend yield (TTM)56.3%

Revenue (annual)385.8M

Net income (annual)-18.7M

Social

What share of all stock conversation is about MED?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Attention	0% 0	0% 0	0% +0	0% 0

Aug 4

Medifast, Inc. ($MED) reported Q2 EPS of -0.28 and revenue of 76.38.
The company is still below cash value, but is expected to show positive income by the next quarter, potentially leading to a 50% increase in stock price.
Medifast, Inc. has a low enterprise value of $50 million, making it a low-risk situation if the company can grow again, but a dead investment for 1-2 years if growth stalls.

Generated by AI

Sentiment

Of the messages about MED that take a side, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Bullish	—	—	100% 0	86.67% +21.96
Bearish	—	—	0% 0	13.33% -21.96

Bullish· Nov 7

Medifast, Inc. (MED) has raised its guidance, indicating a strong performance ahead.
The company's expansion into new international markets, including Hong Kong and Singapore, is expected to drive growth in the first half of 2019.
Long-term investors have seen significant returns on their investment in MED, with one investor reporting a 900% return over 13 years.

Bearish· Jun 5

Medifast, Inc. (MED) has reached a decade low price, with some analysts citing ongoing index selling and short reports.
DA Davidson downgraded MED to Underperform from Neutral with a price target of $17.50, citing lower-than-expected Q1 results and rising costs.
The company's Q1 results were disappointing, with revenue growth expectations pushed out to 2025, and some analysts believe the company is wasting money on unproven turnaround strategies.

Generated by AI

Topics

Of the messages about MED that carry a topic, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y
Announcements	—	—	—	43.33%
Analysts	—	—	—	23.33%
Controversies	—	—	—	0%
Earnings	—	—	—	8.33%
Macro	—	—	—	23.33%
Technical Analysis	—	—	—	1.67%

Community

Of the messages about MED, what share comes from each group?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Regulars	—	—	0%	17.89%
Newcomers	—	—	100%	82.11%

Regulars· Apr 30

Medifast misses on earnings and revenue, beats on revenue guidance, but guides Q2 EPS below analyst estimates.
Regular participants are disappointed with the company's growth and profitability, citing a 25% loss in 2022.
Medifast's Q1 2024 earnings show revenue decline due to market challenges, with a 22.87% pre-market drop in stock price.

Newcomers· Apr 30

The company's Q1 results missed EPS estimates, and Q2 guidance was lower than expected, causing a 14.3% drop in shares on April 27th.
The stock's drop is raising concerns about growth in a tough market, but a solid cash reserve could be a key factor in the company's future.
The stock is now trading at approximately 2.5x cash, and the earnings miss and weak outlook are causing a significant drop in share price.

Generated by AI

News

Medifast's 3.0 Strategy Takes Shape: Can It Restore Profitable Growth?

MED is shifting toward metabolic health with its 3.0 strategy, targeting broader growth, greater efficiency and a return to profitability.

25d agoYahoo Finance

Why Is Medifast (MED) Down 7.6% Since Last Earnings Report?

Medifast (MED) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

27d agoYahoo Finance

Medifast director Kiai Parsa buys $529k in MED stock

1mo agoInvesting.com

Medifast Insider Bought Shares Worth $529,157, According to a Recent SEC Filing

Parsa Kiai, Director, on August 26, 2026, executed a purchase for 43,150 shares in Medifast (MED) fo

1mo agoYahoo Finance

Medifast® Announces the Launch of the Medifast Metabolic Health Institute™

BALTIMORE, August 27, 2026--Medifast, Inc. (NYSE: MED) has announced the launch of the Medifast Metabolic Health Institute, established to advance metabolic health through rigorous research and credible, evidence-based education.

1mo agoYahoo Finance

Can Medifast Capitalize on Rising GLP-1 Use With Metabolic Health?

MED's Trilivy launch marks a major metabolic-health shift, backed by a 10-year roadmap and growing GLP-1 market focus.

1mo agoYahoo Finance

Also Discussed

Investors talking about MED also mention

#	Name	Attention
1	Usana Health Sciences, Inc.USNA	0%new
2	Nu Skin Enterprises Inc.NUS	0%0
3	InMode Ltd.INMD	0%0
4	T. Rowe Price Group Inc.TROW	0%0
5	Kinsale Capital Group, Inc.KNSL	0%0
6	Malibu Boats Inc. Class A Common StockMBUU	0%0
7	Mannatech Inc.MTEX	0%0
8	Alico Inc.ALCO	0%0
9	ProShares UltraShort 7-10 Year TreasuryPST	0%0
10	LifeMD, Inc.LFMD	0%0

Medifast Inc.

Consumer Cyclical
Personal Services

Medifast Inc. is a health and wellness company focused on habit-based, coach-guided lifestyle solutions for weight management and metabolic health. The company’s core offering centers on the OPTAVIA brand, which combines structured nutrition products, meal replacements, and coaching support to help customers build healthier daily routines. Medifast Inc. sells a range of products including shakes, bars, soups, cereals, and other nutrition items designed for convenience and consistency within its program model. Its business serves individuals seeking weight loss and long-term healthy living support, while also relying on a network of independent coaches and digital ordering channels to deliver its services. Headquartered in Baltimore, Maryland, Medifast Inc. plays a specialized role in the broader wellness market by integrating products, guidance, and behavior-change support into a single customer experience.

Website

Location

1501 S. Clinton Street

Baltimore, MD, 21224

United States

Social

What share of all stock conversation is about MED?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Attention	0% 0	0% 0	0% +0	0% 0

Aug 4

Medifast, Inc. ($MED) reported Q2 EPS of -0.28 and revenue of 76.38.
The company is still below cash value, but is expected to show positive income by the next quarter, potentially leading to a 50% increase in stock price.
Medifast, Inc. has a low enterprise value of $50 million, making it a low-risk situation if the company can grow again, but a dead investment for 1-2 years if growth stalls.

Generated by AI

Sentiment

Of the messages about MED that take a side, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Bullish	—	—	100% 0	86.67% +21.96
Bearish	—	—	0% 0	13.33% -21.96

Bullish· Nov 7

Medifast, Inc. (MED) has raised its guidance, indicating a strong performance ahead.
The company's expansion into new international markets, including Hong Kong and Singapore, is expected to drive growth in the first half of 2019.
Long-term investors have seen significant returns on their investment in MED, with one investor reporting a 900% return over 13 years.

Bearish· Jun 5

Medifast, Inc. (MED) has reached a decade low price, with some analysts citing ongoing index selling and short reports.
DA Davidson downgraded MED to Underperform from Neutral with a price target of $17.50, citing lower-than-expected Q1 results and rising costs.
The company's Q1 results were disappointing, with revenue growth expectations pushed out to 2025, and some analysts believe the company is wasting money on unproven turnaround strategies.

Generated by AI

Topics

Of the messages about MED that carry a topic, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y
Announcements	—	—	—	43.33%
Analysts	—	—	—	23.33%
Controversies	—	—	—	0%
Earnings	—	—	—	8.33%
Macro	—	—	—	23.33%
Technical Analysis	—	—	—	1.67%

Community

Of the messages about MED, what share comes from each group?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Regulars	—	—	0%	17.89%
Newcomers	—	—	100%	82.11%

Regulars· Apr 30

Medifast misses on earnings and revenue, beats on revenue guidance, but guides Q2 EPS below analyst estimates.
Regular participants are disappointed with the company's growth and profitability, citing a 25% loss in 2022.
Medifast's Q1 2024 earnings show revenue decline due to market challenges, with a 22.87% pre-market drop in stock price.

Newcomers· Apr 30

The company's Q1 results missed EPS estimates, and Q2 guidance was lower than expected, causing a 14.3% drop in shares on April 27th.
The stock's drop is raising concerns about growth in a tough market, but a solid cash reserve could be a key factor in the company's future.
The stock is now trading at approximately 2.5x cash, and the earnings miss and weak outlook are causing a significant drop in share price.

Generated by AI

Medifast

Social

Aug 4

Bullish· Nov 7

Bearish· Jun 5

Regulars· Apr 30

Newcomers· Apr 30

Medifast's 3.0 Strategy Takes Shape: Can It Restore Profitable Growth?

Why Is Medifast (MED) Down 7.6% Since Last Earnings Report?

Medifast director Kiai Parsa buys $529k in MED stock

Medifast Insider Bought Shares Worth $529,157, According to a Recent SEC Filing

Medifast® Announces the Launch of the Medifast Metabolic Health Institute™

Can Medifast Capitalize on Rising GLP-1 Use With Metabolic Health?

Also Discussed

Medifast Inc.

Company Information

Location

Medifast's 3.0 Strategy Takes Shape: Can It Restore Profitable Growth?

Why Is Medifast (MED) Down 7.6% Since Last Earnings Report?

Medifast director Kiai Parsa buys $529k in MED stock

Medifast Insider Bought Shares Worth $529,157, According to a Recent SEC Filing

Medifast® Announces the Launch of the Medifast Metabolic Health Institute™

Can Medifast Capitalize on Rising GLP-1 Use With Metabolic Health?

Also Discussed

Social

Aug 4

Bullish· Nov 7

Bearish· Jun 5

Regulars· Apr 30

Newcomers· Apr 30